Used in clinical research for the treatment of advanced solid tumors, particularly in patients with NTRK fusion-positive cancers. Demonstrates potent and selective inhibition of tropomyosin receptor kinase (TRK) proteins, which are involved in tumor growth signaling. Shows activity against both wild-type and mutant forms of TRK, including those resistant to earlier generation TRK inhibitors. Administered orally and designed to cross the blood-brain barrier, enabling efficacy in central nervous system tumors. Currently under investigation in phase 1/2 trials to evaluate safety, pharmacokinetics, and anti-tumor activity in adult and pediatric patients.